In-vitro interaction between H2 antagonists and XXXX .

@entity4444 @entity4094 @entity6359 @entity3369 @entity112 @entity35 @entity5616
The interaction between @entity112 H2 antagonists and the neuromuscular blocking drug @entity3369 was investigated in the @entity35 phrenic nerve-hemidiaphragm preparation. @entity4444 alone, in the concentration range 800-4000 microM produced between 14 and 74% @entity4094 with an EC50 (mean +/- s.e.) of 2900 +/- 100 microM. @entity5616 augmented the indirectly-evoked muscle response at concentrations between 30 and 160 microM but at higher concentrations, between 300 and 1800 microM, produced @entity4094 . @entity6359 produced negligible and statistically insignificant (0-5%) @entity4094 at concentrations between 0.3 and 300 microM. @entity4444 (800 microM) shifted the neuromuscular concentration-effect curve of @entity3369 to the left in a parallel manner, while @entity5616 (160 microM) shifted it to the right. The potentiation ratio was 1.90 +/- 0.14 for @entity4444 and 0.62 +/- 0.05 for @entity5616 . @entity6359 (30 microM) did not alter the response to @entity3369 . These data indicate that higher than clinically relevant concentrations of @entity4444 and @entity5616 produce @entity4094 and may potentiate the action of @entity3369 . Low concentrations of @entity5616 may antagonize the action of @entity3369 . @entity6359 , in contrast, lacks significant neuromuscular effects.
